First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Impact ledger

    Eli Lilly and Company (LLY): the developments shaping its investment case

    Follow the evidence affecting Eli Lilly and Company's margins, demand outlook. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.

    Research Eli Lilly and Company · $399/mo

    Test assumptions, examine opportunities, and save your research.

    Material developments

    2026-09-28 · 4 reports
    Eli Lilly Discontinues Sub-Efficacy GLP-1 Drug Amid Pipeline R&D Reallocation
    Channel: Strategic R&D reallocation, pipeline efficiency, and market perception of future growth drivers.
    mixed· 1-3m
    2026-09-28
    Eli Lilly Discontinues Sub-Par GLP-1 Candidate to Refocus Capital on Next-Gen Formulations
    Channel: Strategic capital allocation, R&D efficiency, pipeline optimization
    Bullish· 1-3m
    2026-09-28 · 2 reports
    Eli Lilly drops pipeline GLP-1 candidate on efficacy while maintaining franchise lead
    Channel: Pipeline rationalization, R&D efficiency, investor perception of future growth drivers.
    mixed· 1-3m

    Evidence affecting valuation assumptions

    Each entry names the assumption the evidence touches and how the evidence reads. Direction describes the business mechanism, not a stock-price conclusion.

    DateAssumptionDirectionInterpretation
    2026-08-06marginBullishSurging demand for high-margin GLP-1 agonists (Mounjaro/Zepbound) is driving margin expansion and earnings revisions.
    2026-07-22revenueBullishExpansion of GLP-1 TAM into alcohol use disorder treatment.
    2026-07-13revenueBullishCompany raised 2026 guidance to $82-85B based on Mounjaro and Zepbound growth.
    2026-06-17revenueBullishGLP-1 market projected to reach $95.3B by 2035 with a 12.1% CAGR, driven by oral formulations.
    2026-06-12share_countBullishStock component of consideration dilutes existing acquirer holders.
    2026-06-12net_debtBullishCash component of consideration is typically debt-funded, raising net debt.
    2026-06-12revenueBullishAcquisition adds target revenue to acquirer P&L on close.

    Event impact log

    126 events mapped to LLY since 2026-08-18. Evidence through 2026-09-29.

    DateEventChannelDirectionHorizonImpact
    2026-09-29AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung CancerIncreased competition in the NSCLC market, potentially impacting future market share for their oncology portfolio.Bearish1-3m0.30
    2026-09-29AstraZeneca Submits US NDA for Savolitinib and Tagrisso in MET-Driven Lung CancerIncreased competition in the non-small cell lung cancer (NSCLC) market, particularly for patients with MET-driven resistance.watch1-5y0.30
    2026-09-28Eli Lilly Discontinues Sub-Efficacy GLP-1 Drug Amid Pipeline R&D ReallocationStrategic R&D reallocation, pipeline efficiency, and market perception of future growth drivers.mixed1-3m0.70
    2026-09-28HUTCHMED and GSK Dose First Patient in Phase Ia Trial of KRAS-EGFR Conjugate HMPL-A830Potential future competitive pressure in the oncology market, particularly for KRAS-mutated and EGFR-driven solid tumors.watch1-5y0.20
    2026-09-28Eli Lilly discontinues pipeline GLP-1 candidate following efficacy reviewDirect impact on pipeline value and R&D efficiency perception. Potential reallocation of R&D resources.mixed1-3m0.30
    2026-09-28Eli Lilly Discontinues Experimental GLP-1 Candidate Following Efficacy ReviewStrategic pipeline optimization, reallocation of R&D resources to higher-potential assets, reduced future R&D expenditure on a low-probability candidate.Bullish1-3m0.60
    2026-09-28HUTCHMED doses first patient in Phase Ia trial of KRAS-EGFR conjugate HMPL-A830Potential future competition in oncology, particularly in solid tumors, if HMPL-A830 progresses.watch1-5y0.10
    2026-09-28Eli Lilly drops pipeline GLP-1 candidate on efficacy while maintaining franchise leadPipeline rationalization, R&D efficiency, investor perception of future growth drivers.mixed1-3m0.40
    2026-09-28Eli Lilly Discontinues Early-Stage GLP-1 Candidate Following Efficacy ReviewInvestor sentiment regarding pipeline depth and R&D efficiency; reallocation of R&D resources.mixed1-3m0.30
    2026-09-28Eli Lilly Drops Experimental GLP-1 Candidate as Core Incretin Portfolio Reaches 65% of SalesStrategic focus, R&D efficiency, revenue concentration risk managementmixed1-3m0.60
    2026-09-28HUTCHMED and GSK Initiate Phase Ia Trial for KRAS-EGFR Conjugate TherapyPotential future competitive pressure in the oncology market, specifically for KRAS and EGFR targeted therapies. Successful development could introduce a new competitor.watch3-12m0.20
    2026-09-28Eli Lilly Discontinues Sub-Par GLP-1 Candidate to Refocus Capital on Next-Gen FormulationsStrategic capital allocation, R&D efficiency, pipeline optimizationBullish1-3m0.70
    2026-09-28Eli Lilly Drops Experimental GLP-1 Candidate Following Subpar Efficacy DataStrategic R&D allocation, reduced future R&D expense, increased focus on successful pipeline assets, and maintaining high efficacy standards for commercialized products.Bullish1-3m0.70
    2026-09-27Eli Lilly Drops Experimental Obesity Candidate; Incretins Exceed 65% of Total RevenueDirect impact on R&D pipeline and investor sentiment regarding future growth drivers. Reinforces reliance on existing blockbuster drugs.mixed1-3m0.60
    2026-09-27Eli Lilly Drops Pipeline Obesity Asset as GLP-1 Franchise Exceeds 65% RevenueDirect impact on future pipeline strength and investor sentiment regarding long-term growth sustainability. While current sales are strong, future growth relies on pipeline success.mixed3-12m0.60
    2026-09-27Eli Lilly discontinues developmental obesity drug over unmet efficacy thresholdReduced future revenue potential from a specific pipeline asset, but also reduced R&D expenditure and potential for reallocation of resources to more promising candidates. Increased focus on existing commercial successes and other pipeline assets.mixed1-3m0.60
    2026-09-27Hangzhou Global Open-Source AI Challenge Awards 1M RMB to Peptide AlgorithmPotential for enhanced drug discovery and development efficiency through advanced computational methods, including peptide design.Bullish3-12m0.30
    2026-09-27Eli Lilly Drops Experimental Obesity Candidate While Core GLP-1s Exceed 65% of RevenuePipeline rationalization, increased focus on core high-performing assets, and potential reallocation of R&D resources to more promising candidates or existing GLP-1 production.Bullish1-3m0.70
    2026-09-27Eli Lilly Discontinues Developmental GLP-1 Candidate Over Efficacy StandardsStrategic capital allocation and R&D efficiency. While a discontinuation, it signals a disciplined approach to pipeline management, focusing resources on more promising candidates or existing blockbusters. This could be viewed positively by investors as it avoids future sunk costs on a less effectivBullish1-3m0.60
    2026-09-25Pfizer and Nvidia Back $80M AI Computational Immunology VentureBroader industry trend of increased investment in AI for drug discovery, potentially impacting R&D strategies and competitive dynamics for all major pharmaceutical companies.watch1-3m0.30
    2026-09-25Pfizer and Nvidia Form $80M CytoReason AI Drug Discovery JVBroader industry trend towards AI in drug discovery, potentially increasing R&D efficiency for competitors and setting new industry standards.watch3-12m0.30
    2026-09-25Pfizer and NVIDIA Commit $80M Joint Venture to AI Vaccine Adjuvant DiscoveryAs a major pharmaceutical company with significant R&D investment, Eli Lilly could benefit from the broader trend of AI adoption in drug discovery, potentially improving R&D efficiency and pipeline productivity.Bullish1-5y0.30
    2026-09-24Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety DisorderPotential competitive landscape shift in mental health therapeutics. Lilly has a strong neuroscience pipeline and may be interested in or impacted by new treatments for anxiety disorders.watch3-12m0.10
    2026-09-24InnoCare and Eli Lilly Enter Strategic Licensing Deal with Up to $3.35B in MilestonesStrategic collaboration to expand early-stage drug pipeline, potentially leading to future revenue streams and reduced R&D costs for specific targets.Bullish3-12m0.60
    2026-09-24Hutchmed to Present Phase III Savolitinib NSCLC Trial Results at ESMO 2026 CongressIncreased competition in the NSCLC market, particularly for EGFR-mutated, MET-driven tumors, potentially impacting future market share for their oncology pipeline assets.watch1-5y0.30
    2026-09-24HUTCHMED and AstraZeneca Present Phase III Lung Cancer Data at ESMOIncreased competitive pressure in the EGFR-mutated NSCLC market, particularly for patients developing MET-driven resistance, potentially impacting future market share for competing therapies.Bearish3-12m0.30
    2026-09-24InnoCare and Eli Lilly Enter Strategic Licensing Deal Worth Up to $3.35BStrategic pipeline enhancement through external innovation, potential for future revenue streams from new drug candidates.Bullish3-12m0.60
    2026-09-24InnoCare and Eli Lilly enter multi-target discovery pact worth up to $3.35 billionEli Lilly gains access to potential novel drug candidates and discovery platforms, broadening its early-stage pipeline without the full upfront R&D investment. This could lead to future revenue streams if successful.Bullish3-12m0.60
    2026-09-24Eli Lilly Signs Up to $3.35B Drug Discovery Deal With InnoCareStrategic collaboration to expand drug discovery pipeline, potentially leading to future revenue streams from novel therapies.Bullish1-5y0.60
    2026-09-24Eli Lilly and InnoCare Enter Collaboration Agreement Valued Up to $3.35BStrategic R&D expansion and pipeline diversification through external collaboration. Potential for future revenue streams from successful drug development.Bullish1-5y0.60
    2026-09-23Novo Nordisk Rebrands to Novo and Prepares Oral GLP-1 Launch Against Eli LillyIncreased direct competition in the GLP-1 weight-loss market, particularly from a new oral formulation with a potentially aggressive pricing strategy.Bearish3-12m0.70
    2026-09-23Novo Rebrands to 'Novo' and Launches Oral GLP-1 Pill in Obesity Market PushIncreased direct competition in the lucrative obesity market, potential pricing pressure.Bearish1-5y0.70
    2026-09-23Roche Reports 15.5% Weight Loss in Phase II Trial for EnicepatideIncreased competitive pressure in the GLP-1/GIP market, potentially impacting future market share and pricing power for existing and pipeline assets.mixed3-12m0.60
    2026-09-23Roche Reports 15.5% Weight Loss in Phase II Trial of Dual GLP-1/GIP Agonist EnicepatideIncreased future competition in the GLP-1/GIP agonist market, potentially impacting market share and pricing power for existing and pipeline products.Bearish1-5y0.70
    2026-09-23Novo Rebrands to 'Novo' and Deploys Oral GLP-1 Pill in Market Share DefenseIncreased competitive pressure in the GLP-1 market. Novo's oral formulation and volume pricing could challenge Lilly's market share and pricing power.Bearish1-3m0.70
    2026-09-21Alkermes Announces Positive Phase 1b Results for ALKS 7290 in Adults With ADHDPotential future competition in the ADHD market, particularly for novel mechanisms of action.watch1-5y0.20
    2026-09-21Ionis Plunges Over 40% YTD on Late-Stage Setbacks Despite Bullish TargetsIndirect impact through partnership agreements and potential milestone payments or royalty streams from Ionis's ASO assets.watch3-12m0.10
    2026-09-20Twist Bioscience Surges 31% on Eli Lilly AI Drug Discovery DealEnhanced drug discovery capabilities, potential for accelerated R&D, access to novel data for AI-driven drug development.Bullish3-12m0.60
    2026-09-20Twist Bioscience shares gain 31% on Eli Lilly AI drug discovery pactEnhanced R&D capabilities, potential for accelerated drug discovery, improved R&D efficiency.Bullish3-12m0.30
    2026-09-19Teva presents real-world data showing UZEDY treatment continuity advantageSimilar to J&J, Eli Lilly has products in the broader neuroscience and psychiatric space (e.g., Zyprexa Relprevv, although less prominent than J&J's LAIs). Strong performance by UZEDY could contribute to a more competitive landscape, potentially influencing future market dynamics or R&D investment dwatch3-12m0.10

    Continue this research

    Build your Eli Lilly and Company investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.

    This ledger is regenerated from Market Ontology's public event pipeline. View the LLY entity page →

    Research Eli Lilly and Company · $399/mo